Analyst consensus rating
Relmada Therapeutics Analyst Rating: Strong Buy
Direct answer
Relmada Therapeutics's consensus rating is Strong Buy.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $10.75.
Forecast evidence checked November 16, 2026.
Get free Relmada Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $4.21
- Average price target
- $10.75
- High price target
- $12.00
- Low price target
- $9.00
- Low target gap
- +113.8%
- Target upside
- +155.3%
- High target gap
- +185%
- Target range width
- 71.3%
- Consensus rating
- Strong Buy
- Analysts
- 4
- Evidence date
- November 16, 2026
- Valid through
- November 23, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Relmada Therapeutics?
Relmada Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $10.75.
How far are Relmada Therapeutics's low and high targets from the recorded price?
The low target implies +113.8%, while the high target implies +185%.
How many analysts are included in Relmada Therapeutics's consensus?
The verified consensus includes 4 analysts.
How is Relmada Therapeutics's target upside or downside calculated?
The average target of $10.75 is divided by the recorded price of $4.21, then one is subtracted to produce +155.3%. This does not guarantee a future return.
When was Relmada Therapeutics's analyst forecast verified?
The data was verified on 2026-11-16. The dataset is valid through 2026-11-23.